You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

261 Results
Regimen
Intent: Palliative
Oct 2025
Regimen
Intent: Adjuvant, Palliative
Funding:
Exceptional Access Program
    abemaciclib - For the adjuvant treatment, in combination with endocrine therapy, of adult patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of disease recurrence, according to criteria
ODB - General Benefit
    letrozole
Oct 2025
Regimen
Intent: Adjuvant, Palliative
Funding:
Exceptional Access Program
    abemaciclib - For the adjuvant treatment, in combination with endocrine therapy, of adult patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of disease recurrence, according to criteria
ODB - General Benefit
    anastrozole
Oct 2025
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    fulvestrant
Oct 2025
Document
Document
Document
Document
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell, 
Rare Diseases
Intent: Palliative
Sep 2019
Blog post
Dr. Joan MurphyClinical LeadOntario Cervical Screening Program Are you up to date on your cervical screening? The Ontario Cervical Screening Program...
Oct 2019
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
Jun 2025

Pages